Clinical trials: Kidney Insufficiency
Chronic Kidney Disease, Secondary Hyperparathyroidism
A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis.
- Trial name
- NCT02833857
- Testing
- Etelcalcetide
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 11 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 2, Renal Insufficiency
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00770081
- Testing
- vildagliptin, sitagliptin
- Where
- 87 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis
Acute Renal Failure
Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure
Although conventional hemodialysis removes waste products and corrects fluid imbalance, it does not replace critical absorptive, metabolic, endocrine, and immunologic functions performed by healthy renal tubule cells.
- Trial name
- NCT00511407
- Testing
- Renal tubule assist device
- Where
- 13 sites in United States
- Volunteers
- 58 people
- Sponsor
- RenaMed Biologics
Obesity
Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism.
- Trial name
- NCT00472836
- Testing
- CP-945,598
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
This is an observational study in which data from people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have already started or will start CKD or T2D treatment are collected and studied.
- Trial name
- FINEGUST (NCT05526157)
- Testing
- Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Chronic Kidney Disease, Renal Insufficiency
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.
- Conditions
- Chronic Kidney Disease, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT01742611
- Testing
- ASP1585
- Where
- 5 sites in Japan
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2, Renal Insufficiency
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal…
- Trial name
- NCT00765830
- Testing
- vildagliptin
- Where
- 90 sites in Argentina, Australia and 10 more
- Volunteers
- 349 people
- Sponsor
- Novartis
Hyperkalemia, Chronic Kidney Disease
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
It is hypothesized that zirconium silicate is safe and well tolerated and more effective than placebo (alternative hypothesis) in lowering serum potassium levels in subjects with serum potassium between 5 - 6.0 mmol/l versus no…
- Conditions
- Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction
- Trial name
- NCT01493024
- Testing
- Zirconium silicate (ZS)
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- ZS Pharma, Inc.
Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4
Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
This is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned follow-up of 48 weeks.
- Conditions
- Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4, Glomerulonephritis
- Trial name
- NCT04349683
- Testing
- Jinshuibao
- Volunteers
- 332 people
- Sponsor
- Jemincare
End Stage Renal Disease
Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis
This study is a prospective, multi-center, single-arm study with subjects acting as their own control designed to confirm the safety, performance, and usability of the V Needle, a new safety needle for use during in-clinic…
- Trial name
- Clinic-SAVER (NCT05493423)
- Testing
- V Needle AV Fistula Set
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hemotek Medical Inc
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a…
- Trial name
- NCT06297603
- Testing
- Retatrutide
- Where
- 76 sites in United States, Argentina and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
- Trial name
- NCT01549769
- Testing
- Bardoxolone Methyl
- Volunteers
- 24 people
- Sponsor
- Biogen
Anemia
Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects
Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.
- Trial name
- NCT01318551
- Testing
- BAY85-3934
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Renal Disease
Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence
The purpose of this study is to assess the clinical efficacy of the LCPT En-varsus [Life-Cycle Pharma Tacrolimus] initiated in de novo (Day 0 of transplantation) using the Biopsy Proven Acute Re-jection and iBox (full and…
- Trial name
- NOVOSTART (NCT06960824)
- Testing
- Life-Cycle Pharma Tacrolimus, Kidney transplantation
- Where
- France
- Volunteers
- 165 people
- Sponsor
- Chiesi SAS
Chronic Kidney Disease Requiring Chronic Dialysis
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood).
- Trial name
- NCT06218290
- Testing
- Oxylanthanum Carbonate
- Where
- 7 sites in United States
- Volunteers
- 106 people
- Sponsor
- Unicycive Therapeutics, Inc
Heart Failure, Chronic Kidney Disease
Dapagliflozin Post Marketing Surveillance in HF and CKD
This is an observational, non-interventional, single-arm multicenter study. The objectives of this study are to assess safety and effectiveness of Forxiga in a real world setting in patients who are prescribed with the study drug…
- Trial name
- NCT05134701
- Where
- 26 sites in South Korea
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Renal Impairment
Pharmacokinetics in Subjects With Renal Impairment
This is an open-label, non-randomized, parallel-group, mono-center, single intravenous dose, Phase I trial to investigate the Pharmacokinetic (PK) and safety of cilengitide in subjects with different grades of renal impairment as…
- Trial name
- NCT01504165
- Testing
- cilengitide 2000mg, cilengitide 1000mg, cilengitide > 1000mg and up to 2000mg
- Where
- 2 sites in Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Anemia
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis, with treatment up to 52 weeks.
- Trial name
- NCT02652819
- Testing
- FG-4592
- Where
- 30 sites in China
- Volunteers
- 154 people
- Sponsor
- Kyntra Bio
Chronic Kidney Diseases, Chronic Kidney Disease stage3
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
Leveraging a unique combination of synchronized web and mobile applications, this 3 year SBIR Phase II project will fully develop and pilot test My Kidney Guru-a program that will offer pediatric patients with CKD developmentally…
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage V
- Trial name
- CKD Delp (NCT05630729)
- Testing
- My Kidney Guru
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- 3-C Institute for Social Development
Chronic Kidney Disease Stage 3, Anemia
Desidustat in the Treatment of Anemia in CKD
This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who…
- Conditions
- Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
- Trial name
- DREAM-ND (NCT04012957)
- Testing
- Desidustat Oral Tablet, Darbepoetin Alfa
- Where
- 32 sites in India
- Volunteers
- 588 people
- Sponsor
- Zydus Lifesciences Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.